New Delhi: The central government’s Subject Expert Committee (SEC) is likely to meet on Wednesday on drugmaker Dr. Reddy’s application seeking emergency use authorisation for the Sputnik V vaccine in India. If the SEC gives a nod, Sputnik V will be India’s third vaccine after Covaxin and Covishield, News18 reported.
Dr. Reddy’s has partnered with the Sputnik V vaccine to run clinical trials in India. It had submitted the immunogenicity data after a meeting that was held on February 24.
Dr Reddy’s has partnered with Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India. The Russian vaccine has shown an efficacy of 91.6 %.
Cuttack: A promising youthful life ended in Cuttack on Sunday as a sophomore was electrocuted…
Mumbai: Ever since ‘Kantara’ became a phenomenal hit in 2022, movie lovers have been yearning…
Bhubaneswar: The husband of a sarpanch and a panchayat samiti member were critically injured as…
New Delhi: Pollution in the national Capital is going from bad to worse. As Delhi’s air…
Bhubaneswar: In order to streamline the road construction works, the Odisha government is planning to…
Patna: The trailer of ‘Pushpa 2: The Rule’, one of the year’s most anticipated films, is…
Patna: It was one of the most anticipated events in the Indian film industry -- the…
Bhubaneswar: With Odisha government taking a serious note of unnatural death of elephants, the Forest…